Appendix 1. Definitions of variables included in the analysis

Variable	Definition
DAA medications[12]	DAA drug (brand) dose; duration • Daclatasvir 30 and 60 mg; 12 and 24 weeks • Sofosbuvir 400 mg; 12 and 24 weeks • Elbasvir 50 mg/grazoprevir 100 mg; 12 and 16 weeks • Glecaprevir 100 mg/pibrentasvir 40 mg; 8, 12 and 16 weeks • Paritaprevir 75 mg/ritonavir 50 mg/ombitasvir 12.5 mg plus dasubavir 250 mg/with ribavirin 400 and 600 mg; 12 and 24 weeks • Paritaprevir 75 mg/ritonavir 50 mg/ombitasvir 12.5 mg plus dasubavir 250 mg; 12 weeks • Ledipasvir 90 mg/sofosbuvir 400 mg; 8, 12 and 24 weeks • Sofosbuvir 400 mg/velpatasvir 100 mg; 12 weeks • Sofosbuvir400 mg/velpatasvir 100 mg/voxilaprevir 100 mg; 12 weeks
Treatment completion	Treatment completion was assumed if the full number of expected DAA prescriptions was dispensed to complete the course as specified by the PBS item number: • 8 weeks = two 1-month item claims • 12 weeks = three 1-month item claims • 16 weeks = four 1-month item claims • 24 weeks = six 1-month item claims For example, a DAA item with a 12-week course requires three 1-month prescriptions to be dispensed. The patient was assumed to have completed the treatment if all three prescriptions were dispensed, as recorded by the PBS claims.[8] This is inclusive of 'Regulation 24' prescriptions endorsed to allow all prescriptions to be dispensed and supplied at once[13] Patients were assumed to not have completed treatment if: • less than the expected number of prescriptions was dispensed more than 30 days in total elapsed between the expected and observed date of medication dispensing Exclusion: • Treatment completion was calculated for the patient's first treatment course only, and any re-treatment courses were excluded • Patients were also excluded if their anticipated DAA completion date was after the period covered by the dataset (ie 30 June 2019)
Remoteness	Classified per the Australian Statistical Geography Standard[24] • Major cities • Inner regional • Outer regional • Remote • Very remote
States and territories	• New South Wales • Victoria • Western Australia • South Australia • Queensland • Northern Territory • Tasmania • Australian Capital Territory

Appendix 1. Definitions of variables included in the analysis (Cont'd)

Variable	Definition
Sex	• Male • Female
Age groups	• 0–19 years • 20–29 years • 30–39 years • 40–49 years • 50–59 years • ≥60 years
Treatment duration	• 8 weeks • 12 weeks • 16 weeks • 24 weeks
Prescriber type	• Specialist • General practitioner • Other (eg locum doctors, nurse practitioners) • Unknown
Time period	• March – June 2016 • July – December 2016 • January – June 2017 • July – December 2017 • January – June 2018 • July – December 2018 • January – June 2019

DAA, direct-acting antivirals; PBS, Pharmaceutical Benefits Scheme.